Latest Insider Transactions at Arcutis Biotherapeutics, Inc. (ARQT)
This section provides a real-time view of insider transactions for Arcutis Biotherapeutics, Inc. (ARQT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Arcutis Biotherapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Arcutis Biotherapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 02
2020
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
2,200
-1.22%
|
$39,600
$18.27 P/Share
|
|
Nov 02
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+0.6%
|
$2,200
$1.68 P/Share
|
|
Oct 26
2020
|
Kenneth A. Lock Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,668
+10.88%
|
$16,008
$6.52 P/Share
|
|
Oct 22
2020
|
Kenneth A. Lock Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,695
+12.31%
|
$16,170
$6.52 P/Share
|
|
Oct 15
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,222
+0.68%
|
$0
$0.58 P/Share
|
|
Oct 15
2020
|
Kenneth A. Lock Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+31.25%
|
$45,000
$6.52 P/Share
|
|
Oct 02
2020
|
Jonathan Silverstein Director |
BUY
Open market or private purchase
|
Indirect |
496,000
+14.59%
|
$12,400,000
$25.0 P/Share
|
|
Oct 02
2020
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
496,000
+14.59%
|
$12,400,000
$25.0 P/Share
|
|
Oct 01
2020
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
2,200
-0.61%
|
$57,200
$26.68 P/Share
|
|
Oct 01
2020
|
Howard G. Welgus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+0.61%
|
$2,200
$1.68 P/Share
|
|
Sep 29
2020
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
6,000
-0.53%
|
$180,000
$30.0 P/Share
|
|
Sep 29
2020
|
Todd Franklin Watanabe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+0.52%
|
$6,000
$1.68 P/Share
|
|
Sep 29
2020
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
1,250
-1.25%
|
$37,500
$30.0 P/Share
|
|
Sep 29
2020
|
John W Smither Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
500
-2.05%
|
$15,000
$30.0 P/Share
|
|
Sep 29
2020
|
John W Smither Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+2.01%
|
$500
$1.68 P/Share
|
|
Sep 29
2020
|
David W Osborne Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-5.37%
|
$450,000
$30.0 P/Share
|
|
Feb 04
2020
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
294,117
+6.88%
|
$4,999,989
$17.0 P/Share
|
|
Feb 04
2020
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,685,175
+34.46%
|
-
|
|
Feb 04
2020
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
4,114,962
+35.25%
|
-
|
|
Feb 03
2020
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
558,888
+50.0%
|
$9,501,096
$17.0 P/Share
|